Home › Research › Mild cognitive impairment
GABAergic activity and gamma oscillations in Alzheimer’s disease and mild cognitive impairment: Neuropathology and therapeutic neuromodulatory insights from animal and human studies
Mohammad Ali Salehinejad, Ali Fathi Jouzdani. Brain Network Disorders, 2026-01-30
Topic: Amyloid, tau and blood-test diagnosis
Disruptions in GABAergic activity and alterations in gamma oscillations are key pathological features of AD associated with amyloid-beta (Aβ) plaques. The preclinical models consistently characterize GABAergic dysfunction by selective loss and dysregulation of parvalbumin/somatostatin interneurons, imbalanced tonic–phasic inhibition, and network hyperexcitability, that are associated with memory deficits. Human studies with in vivo spectroscopy and post‑mortem data similarly report reduced GABA levels, altered receptor and transporter expression, and interneuronal vulnerabilities associated with cognitive and affective symptoms.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Salehinejad, M. A., & Jouzdani, A. F. (2026). GABAergic activity and gamma oscillations in Alzheimer’s disease and mild cognitive impairment: Neuropathology and therapeutic neuromodulatory insights from animal and human studies. Brain Network Disorders. https://doi.org/10.1016/j.bnd.2026.01.002
Vancouver
Salehinejad MA, Jouzdani AF. GABAergic activity and gamma oscillations in Alzheimer’s disease and mild cognitive impairment: Neuropathology and therapeutic neuromodulatory insights from animal and human studies. Brain Network Disorders. 2026. doi:10.1016/j.bnd.2026.01.002.
BibTeX
@article{salehinejad2026-98f2bb65,
author = {Salehinejad, Mohammad Ali and Jouzdani, Ali Fathi},
title = {{GABAergic activity and gamma oscillations in Alzheimer’s disease and mild cognitive impairment: Neuropathology and therapeutic neuromodulatory insights from animal and human studies}},
journal = {Brain Network Disorders},
year = {2026},
doi = {10.1016/j.bnd.2026.01.002},
url = {https://doi.org/10.1016/j.bnd.2026.01.002}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Disruptions in GABAergic activity and alterations in gamma oscillations are key pathological features of AD associated with amyloid-beta (Aβ) plaques.
- The preclinical models consistently characterize GABAergic dysfunction by selective loss and dysregulation of parvalbumin/somatostatin interneurons, imbalanced tonic–phasic inhibition, and network hyperexcitability, that are associated with memory deficits.
- Human studies with in vivo spectroscopy and post‑mortem data similarly report reduced GABA levels, altered receptor and transporter expression, and interneuronal vulnerabilities associated with cognitive and affective symptoms.
Why it matters
This review of animal and human studies describes disruptions in GABAergic activity and gamma oscillations as key features of Alzheimer's disease associated with amyloid-beta plaques. It discusses therapeutic neuromodulatory insights but does not report a proven treatment or cure.
Study details
- Study designlongitudinal study
- Participants127
- Evidence strengthModerate
How this study scored 49/100
Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for effect reported and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Brain Network Disorders) |
| Journal's citation record | 0 / 4 | Brain Network Disorders: journal h-index 6 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 2 / 4 | 127 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 2 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 4 / 6 | Cited 8.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Ali Fathi Jouzdani: h-index 10 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | RWTH Aachen University: institution h-index 959 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Total | 49 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.
Related studies in Mild cognitive impairment
Also tagged “machine”
835 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 835 tagged studies.